Skip to content
Türkçe

Google · Funding and deals · Research

DeepMind-born drug discovery company Isomorphic Labs in funding talks at a $40-⁠50 billion valuation

Published: 3 sourcesTürkçe

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, is in early talks to raise new money at a valuation of at least $40 billion, Bloomberg reported on October 8, citing people familiar with the matter. The round could value the company at up to $50 billion, though nothing is final and terms may change. Founded by Demis Hassabis inside Alphabet in 2021 and built on DeepMind’s AlphaFold work, the London-based firm raised a $2.1 billion Series B led by Thrive Capital in May 2026. It has partnerships with Eli Lilly, Novartis and Johnson & Johnson. Isomorphic has not publicly confirmed the report.

Sources

  1. Bloomberg, “Alphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value”, (bloomberg.com)
  2. Isomorphic Labs, “Isomorphic Labs announces Series B investment round”, (isomorphiclabs.com)
  3. Isomorphic Labs, “Isomorphic Labs Enters into a Research Collaboration with Johnson & Johnson”, (isomorphiclabs.com)

About this story

This story was posted on Instagram by @jarrus.tech on Oct. 8, 2026.

Spotted an error in this story? [email protected] · Instagram

This story in Turkish: DeepMind’dan doğan ilaç keşif şirketi Isomorphic Labs, 40-50 milyar dolar değerlemeyle yatırım görüşüyor

On the same topic